SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Judy Garland Synthetic CCD — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientJudy Garland
Date of birth1922-06-10
IdentifiersMRN HR-ML005-SYN-TD; SSN (made up) 000-05-6127
Document date2026-11-01
AuthorMargaret Ellsworth-Diaz, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

Establishing primary care for long-term prescribed sleeping pills and stimulants that began in adolescence: a nonjudgmental assessment, a prescription drug monitoring program review, sleep, mood, anxiety and safety, nutrition, and contraception three months after childbirth. Concerns: She wants to stop needing pills to sleep and to work, without being made to feel she is to blame for them; She is afraid of being unable to sleep or perform during the change; She worries about her weight if she stops the stimulant. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Secobarbital 100 mg oral capsule, two capsules (200 mg) at bedtime; prescribed elsewhere for years; continued by this clinic at the verified dose, seven days at a time, until a supervised withdrawal is planned with addiction medicineTwo capsules at bedtime; no extra dosesOral route1955-06-22 to 1955-07-06completedS
Dextroamphetamine 10 mg oral tablet, one tablet each morning; no extra doses; prescribed elsewhere for weight and energyOne tablet each morningOral route1955-06-22 to 1955-07-20completedS
Dextroamphetamine 5 mg oral tablet, one tablet each morning for two weeks, then stopOne tablet each morning for two weeks, then stopOral route1955-07-20 to 1955-08-03completedS
Sertraline 25 mg oral tablet, one tablet dailyOne tablet dailyOral route1955-06-22 to 1955-06-29completedS
Sertraline 50 mg oral tablet, one tablet dailyOne tablet dailyOral route1955-06-29activeS
Phenobarbital 32.4 mg oral tablet, one tablet three times daily (97.2 mg a day), started in hospital in place of secobarbitalOne tablet three times dailyOral route1955-07-06 to 1955-07-20completedS
Phenobarbital 16.2 mg oral tablet on a written taper schedule in two or three divided doses: 81 mg a day from the four-week visit, lowered by 8.1 to 16.2 mg about every two weeks and paused when needed; dispensed two weeks at a timePer the written taper schedule, in two or three divided dosesOral route1955-07-20activeS
Medroxyprogesterone acetate 150 mg/mL injection, 150 mg into the muscle every 13 weeks150 mg intramuscularly every 13 weeksIntramuscular route1955-06-22activeS
Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for throat pain, no more than 3,000 mg a day, for up to five daysTwo tablets every 6 hours as needed, up to 3,000 mg a dayOral route1955-08-17 to 1955-08-22completedS

Procedures

ProcedureDatesStatusEvidence
Twelve-lead electrocardiogram before continuing a stimulant1955-06-22 to 1955-06-22completedS
Medically managed barbiturate withdrawal: four-day hospital admission to the addiction medicine service to change secobarbital to phenobarbital, with withdrawal scoring, seizure precautions and dose stabilization1955-07-06 to 1955-07-09completedS
Advance care planning conversation, about 17 minutes1955-09-28 to 1955-09-28completedS

Immunizations

DateVaccineStatusEvidence
1955-06-22Tdap vaccinecompletedS
1955-09-28Influenza vaccine, inactivated, this seasoncompletedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
by 1939Stimulant pills for appetite and energy and barbiturate sleeping pills given to her as a teenage studio performer, with dependence on prescribed medicines sinceD (CLM-0003, CLM-0005)
1949Hospital and sanitarium stays in her twenties, publicly described as treatment for exhaustionD (CLM-0007)
1950Suicide attempts reported publicly, including one in 1950; recorded without detailD (CLM-0006)
March 1955Birth of her third child three months before the index visitD (CLM-0010)

Family History

No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.

Health Concerns

ConcernStatusEvidence
She wants to stop needing pills to sleep and to work, without being made to feel she is to blame for themactiveS
She is afraid of being unable to sleep or perform during the changeactiveS
She worries about her weight if she stops the stimulantactiveS

Assessment

Most recent measures: Hemoglobin [Mass/volume] in Blood 12.9 on 1955-10-26; MCV [Entitic mean volume] in Red Blood Cells by Automated count 87 on 1955-10-26; Platelets [#/volume] in Blood by Automated count 268 on 1955-10-26; Ferritin [Mass/volume] in Serum or Plasma 41 on 1955-10-26; Sodium [Moles/volume] in Serum or Plasma 140 on 1955-10-26; Potassium [Moles/volume] in Serum or Plasma 4.2 on 1955-10-26; Creatinine [Mass/volume] in Serum or Plasma 0.68 on 1955-10-26; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1950)/1.73 sq M 118 on 1955-10-26; Glucose [Mass/volume] in Serum or Plasma 82 on 1955-06-22; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 23 on 1955-10-26; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 20 on 1955-10-26; Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma 48 on 1955-10-26; Thyrotropin [Units/volume] in Serum or Plasma 1.9 on 1955-06-22; Total score [DAST-10] 6 on 1955-06-22; Total score [AUDIT-C] 2 on 1955-06-22; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 5 on 1955-10-26; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 5 on 1955-10-26 [S]

Strengths and supports: engagement in care [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Sedative, hypnotic, or anxiolytic use disorder (barbiturate), moderate, with physiological dependence; began with sleeping pills given in adolescence; synthetic modern episode linked to her documented lifelong dependence on prescribed sleeping pillsactiveconfirmed F13.20S — Synthetic modern coding. Tolerance and withdrawal are not counted toward the diagnosis for a medicine taken under medical supervision; five other criteria are met. Person-first language; not a claim about her real diagnosis.
Stimulant use disorder (prescribed amphetamine), mild; began with stimulants given in adolescence for weight and energy; synthetic modern episode linked to her documented pep pillsactiveconfirmed F15.10S — Synthetic modern coding; DSM-5-TR mild stimulant use disorder maps to F15.10. Tolerance and withdrawal are not counted for a supervised prescription.
Chronic insomnia disorder, long-standing, with sleep tied to sleeping pills since adolescenceactiveconfirmed G47.00S — Synthetic modern diagnosis anchored to the documented sleeping pills.
Contraception three months after childbirth while starting an enzyme-inducing drug: injectable progestin chosen because barbiturates, including any used for the withdrawal, weaken contraceptive pills, patches, rings and implantsactiveconfirmed Z30.013S — Synthetic contraception need; the birth is documented.
Major depressive disorder, single episode, moderate, with anxious distress; Mood Disorder Questionnaire negative and no history of mania or hypomaniaactiveconfirmed F32.1S — Synthetic modern diagnosis; not a claim about her real mood. The roster's bipolar disorder lead is not supported by the sources read and is not used.
Acute laryngitis, probably viral, during rehearsals, treated with voice rest and supportive care; resolvedresolvedconfirmed J04.0S — Synthetic acute illness; not a historical claim.

Results

DateMeasureValueUnitReference rangeFlagProvenance
1955-06-22Hemoglobin [Mass/volume] in Blood12.3g/dL12-15.5 g/dLNormalS
1955-06-22MCV [Entitic mean volume] in Red Blood Cells by Automated count86fL80-100 fLNormalS
1955-06-22Platelets [#/volume] in Blood by Automated count28410*3/uL150-400 10*3/uLNormalS
1955-06-22Ferritin [Mass/volume] in Serum or Plasma24ng/mL15-150 ng/mLNormalS
1955-06-22Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
1955-06-22Potassium [Moles/volume] in Serum or Plasma4.1mmol/L3.5-5.1 mmol/LNormalS
1955-06-22Creatinine [Mass/volume] in Serum or Plasma0.66mg/dL0.59-1.04 mg/dLNormalS
1955-06-22Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1950)/1.73 sq M119mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1955-06-22Glucose [Mass/volume] in Serum or Plasma82mg/dL70-99 mg/dLNormalS
1955-06-22Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma21U/L10-35 U/LNormalS
1955-06-22Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma18U/L7-35 U/LNormalS
1955-06-22Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma24U/L5-40 U/LNormalS
1955-06-22Thyrotropin [Units/volume] in Serum or Plasma1.9m[IU]/L0.4-4.5 mIU/LNormalS
1955-06-22Total score [DAST-10]6{score}S
1955-06-22Total score [AUDIT-C]2{score}S
1955-06-22Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]14{score}S
1955-06-22Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]13{score}S
1955-07-20Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]12{score}S
1955-07-20Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]11{score}S
1955-08-31Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]9{score}S
1955-08-31Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]8{score}S
1955-09-28Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]7{score}S
1955-10-26Hemoglobin [Mass/volume] in Blood12.9g/dL12-15.5 g/dLNormalS
1955-10-26MCV [Entitic mean volume] in Red Blood Cells by Automated count87fL80-100 fLNormalS
1955-10-26Platelets [#/volume] in Blood by Automated count26810*3/uL150-400 10*3/uLNormalS
1955-10-26Ferritin [Mass/volume] in Serum or Plasma41ng/mL15-150 ng/mLNormalS
1955-10-26Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
1955-10-26Potassium [Moles/volume] in Serum or Plasma4.2mmol/L3.5-5.1 mmol/LNormalS
1955-10-26Creatinine [Mass/volume] in Serum or Plasma0.68mg/dL0.59-1.04 mg/dLNormalS
1955-10-26Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1950)/1.73 sq M118mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1955-10-26Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma23U/L10-35 U/LNormalS
1955-10-26Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma20U/L7-35 U/LNormalS
1955-10-26Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma48U/L5-40 U/LHighS
1955-10-26Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]5{score}S
1955-10-26Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]5{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
1955-06-22Body height151cmS
1955-06-22Body weight46.5kgS
1955-06-22Body mass index (BMI) [Ratio]20.4kg/m2S
1955-06-22Systolic blood pressure128mm[Hg]S
1955-06-22Diastolic blood pressure84mm[Hg]S
1955-06-22Heart rate98/minS
1955-06-22Respiratory rate16/minS
1955-06-22Body temperature36.8CelS
1955-06-22Oxygen saturation in Arterial blood by Pulse oximetry99%S
1955-06-29Body height151cmS
1955-06-29Body weight46.8kgS
1955-06-29Body mass index (BMI) [Ratio]20.5kg/m2S
1955-06-29Systolic blood pressure124mm[Hg]S
1955-06-29Diastolic blood pressure80mm[Hg]S
1955-06-29Heart rate92/minS
1955-06-29Respiratory rate16/minS
1955-06-29Body temperature36.7CelS
1955-06-29Oxygen saturation in Arterial blood by Pulse oximetry99%S
1955-07-20Body height151cmS
1955-07-20Body weight47.6kgS
1955-07-20Body mass index (BMI) [Ratio]20.9kg/m2S
1955-07-20Systolic blood pressure118mm[Hg]S
1955-07-20Diastolic blood pressure76mm[Hg]S
1955-07-20Heart rate82/minS
1955-07-20Respiratory rate14/minS
1955-07-20Body temperature36.6CelS
1955-07-20Oxygen saturation in Arterial blood by Pulse oximetry99%S
1955-08-31Body height151cmS
1955-08-31Body weight48.9kgS
1955-08-31Body mass index (BMI) [Ratio]21.4kg/m2S
1955-08-31Systolic blood pressure112mm[Hg]S
1955-08-31Diastolic blood pressure72mm[Hg]S
1955-08-31Heart rate72/minS
1955-08-31Respiratory rate14/minS
1955-08-31Body temperature36.7CelS
1955-08-31Oxygen saturation in Arterial blood by Pulse oximetry99%S
1955-10-26Body height151cmS
1955-10-26Body weight50kgS
1955-10-26Body mass index (BMI) [Ratio]21.9kg/m2S
1955-10-26Systolic blood pressure112mm[Hg]S
1955-10-26Diastolic blood pressure70mm[Hg]S
1955-10-26Heart rate68/minS
1955-10-26Respiratory rate14/minS
1955-10-26Body temperature36.6CelS
1955-10-26Oxygen saturation in Arterial blood by Pulse oximetry99%S
1955-09-28Body height151cmS
1955-09-28Body weight49.4kgS
1955-09-28Body mass index (BMI) [Ratio]21.7kg/m2S
1955-09-28Systolic blood pressure110mm[Hg]S
1955-09-28Diastolic blood pressure70mm[Hg]S
1955-09-28Heart rate70/minS
1955-09-28Respiratory rate14/minS
1955-09-28Body temperature36.6CelS
1955-09-28Oxygen saturation in Arterial blood by Pulse oximetry99%S
1955-08-17Body height151cmS
1955-08-17Body weight48.4kgS
1955-08-17Body mass index (BMI) [Ratio]21.2kg/m2S
1955-08-17Systolic blood pressure116mm[Hg]S
1955-08-17Diastolic blood pressure74mm[Hg]S
1955-08-17Heart rate84/minS
1955-08-17Respiratory rate16/minS
1955-08-17Body temperature37.6CelS
1955-08-17Oxygen saturation in Arterial blood by Pulse oximetry98%S

Encounters

DatePurposeStatusProvenance
1955-06-22Establishing primary care for long-term prescribed sleeping pills and stimulants that began in adolescence: a nonjudgmental assessment, a prescription drug monitoring program review, sleep, mood, anxiety and safety, nutrition, and contraception three months after childbirthfinishedS
1955-06-29One-week review with the addiction medicine consultation: planning a supervised barbiturate withdrawalfinishedS
1955-07-20Four-week review eleven days after a supervised hospital change from secobarbital to phenobarbital: starting the outpatient taper and the stimulant taperfinishedS
1955-08-31Ten-week review: phenobarbital taper, life after stopping the stimulant, sleep, mood, weight and workfinishedS
1955-10-26Four-month review: phenobarbital taper, sleep, mood, laboratory checks and the plan to finishfinishedS
1955-09-28Periodic adult preventive visitfinishedS
1955-08-17Same-day sick visit for acute laryngitisfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Safe prescribing of controlled drugs: one prescriber and one pharmacy, a prescription drug monitoring program check before every controlled-substance prescription, a written shared treatment agreement, urine drug testing explained as part of care, seven-day supplies at first, a locked box, and take-back of unused capsulescompletedGL-BZD-TAPER-2025, GL-CDC-PDMPS
Addiction medicine consultation to confirm the diagnoses, plan a safe barbiturate withdrawal and taper, and advise on stopping the stimulantcompletedGL-BZD-TAPER-2025, GL-ASAM-AWM-2020, GL-ASAM-STIM-2024S
Supervised barbiturate withdrawal: a short hospital admission to change secobarbital to phenobarbital with withdrawal scoring and seizure precautions, then a slow outpatient phenobarbital taper of no more than about 20% every two weeks, slower toward the end, paused for withdrawal symptoms, illness or a major performance, never stopped abruptly; no benzodiazepine or Z-drug in its place; no alcoholcompletedGL-BZD-TAPER-2025, GL-ASAM-AWM-2020S
Stimulant: dextroamphetamine held at one fixed morning dose until phenobarbital is stable, then 5 mg for two weeks and stopped, with mood, sleep and appetite checks; no other stimulantcompletedGL-ASAM-STIM-2024S
Insomnia: cognitive behavioral therapy for insomnia as first-line treatment, adapted to late performances (a fixed wake time, a wind-down routine after shows, sleep restriction only after the taper is stable), with a sleep diary; no new hypnoticcompletedGL-ACP-INSOMNIA-2016, GL-AASM-INSOMNIA-2017S
Depression and anxiety: PHQ-9 and GAD-7 at each visit, sertraline, weekly psychotherapy, the Mood Disorder Questionnaire before the antidepressant, a structured safety assessment with a written safety plan, means safety and the 988 Suicide & Crisis Lifeline, and safety review at every visitcompletedGL-CMID-2026, GL-USPSTF-DEP-2023, GL-SUICIDE-2024S
Nutrition and weight without stigma: regular meals and snacks around rehearsals, a dietitian visit, no weight-loss target and no dieting drugs, and screening for disordered eatingcompletedGL-ASAM-STIM-2024S
Contraception that barbiturates do not weaken: medroxyprogesterone injection every 13 weeks, after a negative pregnancy test, with an intrauterine device as an alternativecompletedGL-CDC-MEC-2024S
Naloxone not prescribed: she takes no opioid, has no opioid prescription in the monitoring program, her urine test shows no opioids or fentanyl, and all her pills come from a pharmacy; naloxone does not reverse a barbiturate overdose. To be offered at once if an opioid is ever prescribed or any pill comes from outside a pharmacycompletedGL-ASAM-STIM-2024, GL-CDC-PDMPS
Work: taper steps scheduled away from major performances, a written plan for late nights and travel, and letters she controlscompletedGL-BZD-TAPER-2025S

Goals

GoalTargetStatusOutcomeProvenance
Change from secobarbital to phenobarbital under supervision without a withdrawal seizure or delirium1955-07-20completedFour-day supervised admission; no seizure, delirium or severe withdrawalS
Lower the phenobarbital dose slowly, at no more than about 20% every two weeks, toward stopping1955-10-26active97.2 mg a day at discharge to 32.4 mg a day at four months; two pauses when needed; taper continuingS
Stop dextroamphetamine with a short taper and no return to it1955-08-31completedStopped after a two-week taper; tiredness for about two weeks, then betterS
Sleep six hours or more on most nights using CBT for insomnia1955-10-26activeAbout six hours on most nights; rebound wakefulness after each dose step settles within a weekS
PHQ-9 below 5 by six months1955-10-26activePHQ-9 14 to 5 at four months; responseS
Regular meals and weight she is comfortable with, without dieting drugs1955-10-26completedThree meals on most days; weight up 3.5 kg to a BMI of 21.9; she says she feels strongerS

Functional Status

Mental Status

Structured synthetic safety assessment on 1955-06-22: current ideation absent, intent absent, plan absent. Outpatient care with close follow-up. Risk factors reviewed without detail: past suicide attempts reported in earlier years, a sedative use disorder, depression, the months after childbirth, and the low mood that can follow stopping a stimulant. Barbiturates are dangerous in overdose, so means safety is part of the plan: she agreed to take the unused capsules from earlier prescriptions to a pharmacy take-back at the next visit, to keep the current supply in a locked box, and to receive no more than seven days at a time. No alcohol with the barbiturate. A written safety plan was made with her, and the 988 Suicide & Crisis Lifeline (call or text 988) was saved in her phone. Safety is reviewed at every visit [S]